Although MEK inhibition was shown to block naïve CD8+ T-cell priming, it protected the tumor-infiltrating CD8+ T cell from cell death driven by chronic TCR stimulation with sparing of cytotoxic activity, thus resulting in a synergistic and durable tumor regression, given that either agent alone was only modestly effective [98]. Here, MAP2K7 is linked to neoplasm.